Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 1)] Publisher



Avagimyan AA11, 12 ; Sheibani M13, 14 ; Trofimenko AI15 ; Lysov EE15 ; Khamidova FM16 ; Aznauryan AZ17 ; Sukiasyan LM18 ; Sahakyan KT17 ; Gevorgyan TR19 ; Tatoyan MR17 ; Mkrtchyan GL17 ; Meltonyan GL17 ; Petrosyan AR20 ; Martemyanova LA21 Show All Authors
Authors
  1. Avagimyan AA11, 12
  2. Sheibani M13, 14
  3. Trofimenko AI15
  4. Lysov EE15
  5. Khamidova FM16
  6. Aznauryan AZ17
  7. Sukiasyan LM18
  8. Sahakyan KT17
  9. Gevorgyan TR19
  10. Tatoyan MR17
  11. Mkrtchyan GL17
  12. Meltonyan GL17
  13. Petrosyan AR20
  14. Martemyanova LA21
  15. Petrosyan RR22
  16. Urazova OI23, 24
  17. Pogosova NV10, 12
  18. Sarrafzadegan N25

Source: Innovative Medicine of Kuban Published:2024


Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes. © 2024 Scientific Research Institute — Ochapovsky Clinical Regional Hospital no. 1. All rights reserved.
Related Docs
View other Related Docs
1. Sodium-Glucose Co-Transporter 2 Inhibitors (Sglt2i); As a Preventive Factor of Kidney Failure in Patients With Type 2 Diabetes; a Meta-Analysis of Randomized Controlled Trials, Journal of Renal Injury Prevention (2021)
2. Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2); [Протективный Потенциал Ингибиторов Натрий-Глюкозного Котранспортера 2 Типа В Клинике Внутренних Болезней (Часть 2)], Innovative Medicine of Kuban (2025)
3. Dapagliflozin in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis on Randomized, Double-Blind, Placebo-Controlled Multicenter Trials, Journal of Nephropathology (2025)
Experts (# of related papers)
View all Related Experts
Davood Shafie (3)
Nizal Sarrafzadegan (2)
Other Related Docs
4. Effect of Sodium-Glucose Transporter 2 Inhibitors on the Risk of Contrast-Induced Acute Kidney Injury; a Systematic Review and Meta-Analysis, Journal of Renal Injury Prevention (2025)
5. Association Between Sglt2 (Sodium-Glucose Cotransporter-2) Inhibitors and Bladder Cancer in Individuals With Type 2 Diabetes; a Systematic Review and Meta-Analysis, Journal of Nephropathology (2023)
6. Antianginal Effects of Empagliflozin in Patients With Type 2 Diabetes And Refractory Angina; a Randomized, Double-Blind Placebo-Controlled Trial (Empt-Angina Trial), Clinical Cardiology (2024)
7. Investigating the Association Between the Administration of Sglt-2 Inhibitors and the Risk of Urinary Tract Infection; a Systematic Review and Meta-Analysis, Journal of Renal Injury Prevention (2024)
8. Sodium-Glucose Cotransporter 2 Inhibitors and Pulmonary Hypertension a Systematic Review, Cardiology in Review (2025)
9. The Impact of Sodium-Glucose Co-Transporter-2 Inhibitors on Serum Sodium and Potassium in Patients With Heart Failure: A Systematic Review and Meta-Analysis, BMC Cardiovascular Disorders (2025)
10. Administration of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Patients With Diabetes: A Systematic Review and Meta-Analysis, Journal of Nephropathology (2023)
11. Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Insulin Resistance; a Systematic Review and Meta-Analysis, Acta Diabetologica (2023)
12. Bright Renoprotective Properties of Metformin: Beyond Blood Glucose Regulatory Effects, Iranian Journal of Kidney Diseases (2013)
13. Reducing Cardiac Steatosis: Interventions to Improve Diastolic Function: A Narrative Review, Current Problems in Cardiology (2023)
14. The Effects of Blocking Angiotensin Receptors on Early Stages of Diabetic Nephropathy, International Journal of Preventive Medicine (2012)
15. The Prescription Rate of Sglt Inhibitors and Glp1 Receptor Agonists in Patients With Type 2 Dm, According to the Ada and Esc Criteria in Three Diabetes Centers in Iran, Journal of Isfahan Medical School (2025)
16. Effects of Losartan on Capillary Density in Cardiac Muscles of Diabetic Rats, Journal of Isfahan Medical School (2012)
17. Effects of Losartan on Capillary Density in Cardiac Muscles of Diabetic Rats, Journal of Isfahan Medical School (2012)
18. Metformin and Renal Protection, Journal of Isfahan Medical School (2014)
19. The Combined Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on the Progressing of Kidney Disease in Patients With Type 2 Diabetes Compared to Single Administration of Each of These Two Drugs, Journal of Isfahan Medical School (2016)
20. Comparative Study of Nephroprotective Effects of Resveratrol and Silymarin in Diabetic Rats; an Experimental Histopathologic Study, Journal of Nephropharmacology (2024)